INNOVATION ARTICLES
-
Why Ending Rh Disease Requires More Than A Breakthrough (Part 3 of 3)
Rh disease has been preventable for decades. Yet babies still die worldwide because access, supply, and infrastructure have not caught up.
-
Chinese Competition And The Future Of Science: Insights From The U.S. Science Summit
At BiotechTV’s U.S. Science Summit, biotech leaders discussed China, AI, scientific storytelling, and what it will take to protect U.S. innovation.
-
Rethinking The Blueprint For Bone Regeneration: The Next Evolution In Orthobiologics
Next-generation orthobiologics could transform spinal fusion by enabling targeted bone regeneration, improving safety, and reducing reliance on traditional grafts and hardware.
-
Pharmacogenomics In Oncology: A Pharmacokinetic Perspective
The outcome of a medical treatment is not solely determined by the efficacy of the drug itself. It also depends on the patient’s genetic makeup, biological characteristics of the disease, and individual clinical factors.
-
From Valency To Vaccine Design: The Changing Competitive Landscape In Pneumococcal Vaccines
Pneumococcal vaccination remains one of the strongest success stories in bacterial disease prevention, but the residual burden is now posing new challenges.
-
Rhogam's Unconventional History And Why There Is No True Synthetic Replacement (Part 2 of 3)
Rhogam transformed Rh disease prevention, but its plasma-derived, polyclonal biology has resisted decades of synthetic anti-D replacement efforts.
INNOVATION ARTICLES. APP NOTES, CASE STUDIES. & WHITE PAPERS
-
With most drug candidates failing before approval, researchers need better ways to predict human responses. Gain insight into how advances in human-relevant modeling are helping improve decisions.
-
Traditional models often fall short in women’s health research. Learn how human-relevant Organ-Chip systems are providing new ways to study vaginal, cervical, and uterine biology.
-
Non-PEG stabilizer lipids may offer a new path for LNP design. Combining strong colloidal performance with greater chemical flexibility helps address growing concerns around PEG-related immunogenicity.
-
Personalized cancer vaccines are advancing quickly, but effective delivery remains a major hurdle. Learn how mRNA and lipid nanoparticle design influence targeting, endosomal escape, and repeat dosing.
-
Gain insight into how nebulized mRNA lipid nanoparticles show preclinical success in lung delivery, offering fresh momentum for inhaled gene therapies targeting respiratory diseases.
-
Lipid nanoparticles are redefining immune cell engineering. Delve into new data that demonstrates the performance across multiple cell types and bioreactor systems, supporting their potential workflows.
INNOVATION SOLUTIONS
-
Macrocycles expand drug discovery into previously inaccessible targets. With validated success and flexible approaches, they provide a powerful path for tackling the most challenging biology.
-
Curia’s in vivo Discovery Immunology team offers high-performance hybridoma-based technologies to help clients discover great antibodies that make a difference.
-
Curia offers phage and eukaryotic-based yeast display platforms for in vitro discovery and engineering of potent antibody candidates for therapeutic or diagnostic use. High-affinity functional antibodies are routinely selected against a wide range of conventional or challenging targets (e.g. GPCRs) using customized or in-licensed state-of-the-art libraries.
-
Curia has extensive experience with constructing and producing antibodies in our mammalian platforms.
-
Evaluating the developability of therapeutic drug candidates early can help circumvent potential issues in late-stage development.
-
Our collaborative approach, proven track record, and deep technical expertise enable us to efficiently advance promising candidates, reduce development risk, and help transform innovative ideas into successful therapeutic realities.
-
Curia’s expert scientists use advanced technology to produce and analyze high-quality recombinant proteins.
-
Make the most of your molecule with integrated antibody discovery, engineering, and production capabilities designed to accelerate lead identification and optimization.
-
The Antibody Center at Curia provides end-to-end services in antibody discovery, engineering, and development.
-
Our Biologics services provide comprehensive Molecular Biology services at facilities in California and Massachusetts, offering a variety of services.
-
Curia has decades of experience in recombinant protein production.
-
Whether you require a particular expertise or a complete, experienced integrated small molecule discovery team, Curia can provide a high-performance solution to help turn your vision into reality.
-
For more than 30 years Curia has been meeting the custom synthesis needs of our clients.
-
Integrated drug discovery greatly benefits programs by blending various scientific disciplines into a unified team focused on your project.